Why does Ocrelizumab cost more for Relapse Remitting MS than for Primary Progressive?

In this video Rachel interviews Professor Gavin Giovannoni who is a Consultant Neurologist. The interview was filmed by Rob

Video transcript

Ocrelizumab was being reviewed by NICE as the first licensed treatment for Primary Progressive MS. NICE aren’t recommending it because the price tag will be different for the NHS for primary progressive MS, than the current price for treating Relapsing Remitting MS. Prof G explains how the same treatment can have two different price tags.

If you think it’s unfair that NICE aren’t recommending the first licensed drug for primary progressive MS, Gavin recommends writing to your MP. We’ve put together a template letter to download on this link. https://goo.gl/K2kxg3

MS Reporter: Rachel

Expert: Gavin Giovannoni, Consultant Neurologist, BARTS, London


More videos about Treatment category

Leave a Reply

Have you found this video useful? Please let us know by filling in this short survey.
Join the Shift.ms communityclose